Pharmaceuticals, Biotechnology and Life Sciences
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive…
Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Expected to be Completed in Fourth Quarter 2019…
Statistical Significance Not Achieved for Primary or Secondary Endpoints Due to High Rates of Disease Resolution in Vehicle-Treated Patients, but Activity of Reproxalap Observed to be Consistently Greater than Vehicle
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve…